<?xml version="1.0" encoding="UTF-8"?>
<ref id="cit0040">
 <label>40.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Angelidou</surname>
    <given-names>A</given-names>
   </name>, 
   <name name-style="western">
    <surname>Diray-Arce</surname>
    <given-names>J</given-names>
   </name>, 
   <name name-style="western">
    <surname>Conti</surname>
    <given-names>MG</given-names>
   </name>, 
   <name name-style="western">
    <surname>Smolen</surname>
    <given-names>KK</given-names>
   </name>, 
   <name name-style="western">
    <surname>van Haren</surname>
    <given-names>SD</given-names>
   </name>, 
   <name name-style="western">
    <surname>Dowling</surname>
    <given-names>DJ</given-names>
   </name>, 
   <name name-style="western">
    <surname>Husson</surname>
    <given-names>RN</given-names>
   </name>, 
   <name name-style="western">
    <surname>Levy</surname>
    <given-names>O</given-names>
   </name>
  </person-group>
  <article-title>BCG as a case study for precision vaccine development: lessons from vaccine heterogeneity, trained immunity, and immune ontogeny</article-title>. 
  <source>Front Microbiol</source>. 
  <year>2020</year>;
  <volume>11</volume>:
  <fpage>332</fpage>
  <comment>Published 2020 Mar 11</comment>. doi:
  <pub-id pub-id-type="doi">10.3389/fmicb.2020.00332</pub-id>.
  <pub-id pub-id-type="pmid">32218774</pub-id>
 </mixed-citation>
</ref>
